BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12790512)

  • 1. Hepatitis C virus therapies: current treatments, targets and future perspectives.
    Walker MP; Appleby TC; Zhong W; Lau JY; Hong Z
    Antivir Chem Chemother; 2003 Jan; 14(1):1-21. PubMed ID: 12790512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C: therapeutic perspectives.
    Cornberg M; Wedemeyer H; Manns MP
    Forum (Genova); 2001; 11(2):154-62. PubMed ID: 11948360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic evolution of therapy for chronic hepatitis C: how will novel agents be incorporated into the standard of care?
    Zeuzem S; Nelson DR; Marcellin P
    Antivir Ther; 2008; 13(6):747-60. PubMed ID: 18839776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future therapy of hepatitis C.
    McHutchison JG; Patel K
    Hepatology; 2002 Nov; 36(5 Suppl 1):S245-52. PubMed ID: 12407600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of chronic hepatitis C].
    Rókusz L
    Orv Hetil; 2004 Aug; 145(32):1649-53. PubMed ID: 15384863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy of hepatitis C: from empiricism to eradication.
    Pawlotsky JM
    Hepatology; 2006 Feb; 43(2 Suppl 1):S207-20. PubMed ID: 16447262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promising candidates for the treatment of chronic hepatitis C.
    Walker MP; Yao N; Hong Z
    Expert Opin Investig Drugs; 2003 Aug; 12(8):1269-80. PubMed ID: 12882616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
    Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E
    Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New treatments for chronic hepatitis C virus infection.
    Corouge M; Pol S
    Med Mal Infect; 2011 Nov; 41(11):579-87. PubMed ID: 21764234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New HCV therapies on the horizon.
    Vermehren J; Sarrazin C
    Clin Microbiol Infect; 2011 Feb; 17(2):122-34. PubMed ID: 21087349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hepatitis C virus infection--after 12 years. Advances in the management of chronic hepatitis C].
    Pár A
    Orv Hetil; 2002 Dec; 143(48):2667-74. PubMed ID: 12501575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hepatitis C revolution part 1: antiviral treatment options.
    Thiagarajan P; Ryder SD
    Curr Opin Infect Dis; 2015 Dec; 28(6):563-71. PubMed ID: 26524328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Inhibitors of hepatitis C virus--current standards and status of investigations].
    Godzik P; Komorowski M; Cielecka-Kuszyk J; Madaliński K
    Przegl Epidemiol; 2010; 64(4):473-8. PubMed ID: 21473060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?
    Michielsen P; Ho E; Francque S
    Minerva Gastroenterol Dietol; 2012 Mar; 58(1):65-79. PubMed ID: 22419005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.
    Ferraro D; Bonura C; Giglio M; Di Stefano R; Almasio PL; Di Marco V; Craxì A; Cacciola I; Squadrito G; Raimondo G
    J Biol Regul Homeost Agents; 2003; 17(2):172-5. PubMed ID: 14518718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study.
    Terrier B; Lapidus N; Pol S; Serfaty L; Ratziu V; Asselah T; Thibault V; Souberbielle JC; Carrat F; Cacoub P
    World J Gastroenterol; 2015 May; 21(18):5647-53. PubMed ID: 25987791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapy of hepatitis C].
    Moradpour D; Blum HE
    Praxis (Bern 1994); 2002 May; 91(22):977-82. PubMed ID: 12094432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and evolving therapies for hepatitis C.
    Moradpour D; Blum HE
    Eur J Gastroenterol Hepatol; 1999 Nov; 11(11):1199-202. PubMed ID: 10563526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin.
    Selvapatt N; Habibi MS; Brown A
    J Med Virol; 2015 Oct; 87(10):1716-21. PubMed ID: 25914248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of hepatitis C virus infection].
    Zeuzem S
    Praxis (Bern 1994); 2005 May; 94(18):721-6. PubMed ID: 15938383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.